Compare

Genfit S.A./€GNFT

1D1W1M3M6MYTD1Y5YMAX

About Genfit S.A.

Genfit S.A. is a French biopharmaceutical company focused on developing therapeutics and diagnostic solutions for metabolic and liver-related diseases. Known for its work in treating nonalcoholic steatohepatitis (NASH) and other liver diseases, Genfit offers key products including investigational drugs such as elafibranor and diagnostic tests like NIS4 for identifying NASH. Founded in 1999, the company is headquartered in Loos, France. Its strategic positioning lies in addressing unmet medical needs in liver health, supported by a robust research and development pipeline. Genfit's competitive strengths include expertise in nuclear receptor pathways and strategic partnerships with other biopharmaceutical firms.
Ticker
€GNFT
Sector
Health
Primary listing
PAR
Employees
180
Headquarters
Loos, France
Website
www.genfit.com

Genfit S.A. Metrics

BasicAdvanced
€547M
-
-€2.04
1.19
-

What the Analysts think about Genfit S.A.

Analyst ratings (Buy, Hold, Sell) for Genfit S.A. stock.
Analyst projections of the future price of Genfit S.A. stock.

Bulls say / Bears say

Iqirvo royalties more than tripled to €21.0 million in H1 2026, and Ipsen raised its peak annual PBC sales target to €1 billion after a Phase 3 study found ALP normalisation in 85% of treated patients versus 23% on placebo. That gives Genfit a growing commercial income stream without having to market the drug itself. (GENFIT)
Medicare coverage for Labcorp’s NASHnext test, based on Genfit’s NIS technology, began in the US in August 2026. This creates a potential second growth engine in MASH diagnosis, although the company’s estimate of more than $1.5 billion in peak US sales by 2033 is a forecast, not current revenue. (GENFIT)
Genfit had €113.8 million in cash at June 2026 and expects it to fund operations beyond the end of 2028. This gives the company time to advance its clinical programmes before needing to seek more capital, subject to its stated assumptions. (GENFIT)
H1 revenue fell to €21.1 million from €33.5 million a year earlier, while the net loss widened to €26.1 million from €10.0 million. The comparison is affected by a €26.5 million milestone recognised in the prior-year period, but it still shows how lumpy income and sizeable losses remain. (GENFIT)
The projected cash runway beyond 2028 depends on future Ipsen sales milestones and Genfit drawing the final optional tranche of royalty financing. Almost all Iqirvo royalties are also being used to repay that financing, which limits how much commercial growth immediately benefits Genfit’s cash position. (GENFIT)
Evidence for GNS561 in cholangiocarcinoma is still preliminary: the Phase 1b update covered 19 patients, with about half showing stable disease at week six and only one remaining stable through week 30. Genfit is expanding the study to test higher doses, so meaningful efficacy remains unproven. (Euronext)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.

Genfit S.A. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Genfit S.A. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.